pubmed-article:18516079 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C0014644 | lld:lifeskim |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C0024314 | lld:lifeskim |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C0332835 | lld:lifeskim |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C0687676 | lld:lifeskim |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C1419875 | lld:lifeskim |
pubmed-article:18516079 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
pubmed-article:18516079 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:18516079 | pubmed:dateCreated | 2008-8-13 | lld:pubmed |
pubmed-article:18516079 | pubmed:abstractText | Fatal problems encountered in allogeneic stem cell transplantation include EBV reactivation and post transplant lymphoproliferative disorders (PTLDs) with high mortality rates. We performed a retrospective analysis in all consecutive adult and pediatric EBV reactivations and PTLD during a period of 8.5 years. There were 26 patients with EBV reactivation/PTLD out of a total of 854 transplantations giving an overall incidence of 3.0%. Specifically, the incidence of EBV-PTLD was 1.3%, whereas that of EBV reactivation was 1.8%. Median age was 46.0 and 11.0 years in the adult and pediatric patients, respectively. There were high rates (54%) of concomitant bacterial, viral, fungal and parasitic infections at the time of EBV manifestation. Variable treatment regimens were applied including in most cases an anti-CD20 regimen often in combination with virustatic compounds, polychemotherapy or donor lymphocytes. The mortality rates were 9 of 11 (82%) in patients with EBV-PTLD and 10 of 15 (67%) in patients with reactivation. Only 7 of 26 patients (27%) are alive after a median follow-up of 758 days (range 24-2751). The high mortality rates of EBV reactivation and of EBV-PTLD irrespective of multimodal treatment approaches emphasize standardization and optimization of post transplant surveillance and treatment strategies to improve control of these often fatal complications. | lld:pubmed |
pubmed-article:18516079 | pubmed:language | eng | lld:pubmed |
pubmed-article:18516079 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18516079 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18516079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18516079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18516079 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18516079 | pubmed:month | Aug | lld:pubmed |
pubmed-article:18516079 | pubmed:issn | 0268-3369 | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:ZanderA RAR | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:KabischHH | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:AyubMM | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:MutaHH | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:ErttmannRR | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:PetersenLL | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:SobottkaII | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:BachetWW | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:KroegerNN | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:LellekHH | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:ZabelinaTT | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:OcheniSS | lld:pubmed |
pubmed-article:18516079 | pubmed:author | pubmed-author:WolschkeCC | lld:pubmed |
pubmed-article:18516079 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18516079 | pubmed:volume | 42 | lld:pubmed |
pubmed-article:18516079 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18516079 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18516079 | pubmed:pagination | 181-6 | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:meshHeading | pubmed-meshheading:18516079... | lld:pubmed |
pubmed-article:18516079 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18516079 | pubmed:articleTitle | EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. | lld:pubmed |
pubmed-article:18516079 | pubmed:affiliation | Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. | lld:pubmed |
pubmed-article:18516079 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18516079 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18516079 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18516079 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18516079 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18516079 | lld:pubmed |